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four months postoperatively. Perfusate waste test demonstrated various revascularization growth factors
secreted by TNCs. The patient received two cycles of chemotherapy and 30 Gy radiotherapy thereafter
without complications related to the TE substitute. CONCLUSIONS In-vivo bioreactor design combines
the traditionally separated in vitro 3D cell-scaffold culture system and the in vivo regenerative processes
associated with TE substitutes, while treating the recipients as bioreactors for their own TE prostheses.
This design can be applied clinically. We also proved for the first time that TE airway substitute is able
to tolerate chemo-radiotherapy and suitable to be used in cancer treatment.
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Introduction
Long-segment airway defect remains a challenge in 
clinic (1). Tissue engineering and regenerative medicine 
provide a promising solution (2-4). Classic TE technique is 
compose of two absolutely separated stages, namely, in-vitro 
cell-scaffold three-dimensional (3D) culture and in-vivo 
TE substitute regenerative processes (5). Unfortunately, 
it has proven to be extremely difficult to reconstruct the 
capillary net inside the TE organ (6). Previous studies 
have demonstrated that implanted TE substitute get the 
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nutrition initially from tissue fluid infiltration and finally 
from vessel in-growth from the surround normal tissue. 
The final revascularization process normally takes several 
weeks. The central part of the TE substitute suffers from 
ischemia at the early stage of implantation. The majority 
of pre-seeded cells will die and the regenerative niche 
deteriorates (7). Recent dispute in Prof. Paolo Macchiarini’s 
work on TE trachea challenge the rationality of traditional 
tissue engineering technique application in TE airway 
reconstruction (8). 
To deal with this technical problem, we designed an 
“in-vivo bioreactor” design defined as implanted TE airway 
substitutes perfused with intra-scaffold medium flow created 
by an extracorporeal portable pump system for in situ organ 
regeneration (9). In pilot tests, we demonstrated three 
main advantages of this design. Firstly, continuous medium 
perfusion keeps the pre-seeded cells alive before final 
revascularization; secondly, it functions as a cell re-seeding 
system whereby cells can be harvested and seeded into the 
implanted TE airway substitute through in-vivo bioreactor 
catheter similar to routine infusion; thirdly, various growth 
factors can be added into the perfusate as an efficient way 
to guarantee functional growth factors concentration inside 
the implanted TE airway (10,11).
In the clinical setting, lung cancer invading the airway 
is common with around 50% 5-year survival rate after 
a complete resection (12). TE airway application in 
lung cancer patients is controversial due to concerns of 
compromised regenerative process caused by adjuvant 
chemo-radiotherapy that is essential in multidisciplinary 
treatment of lung cancer. Here, we present a late stage 
lung cancer patient who underwent left main bronchus 
resection, left upper lobectomy, and left lower superior 
segment resection. A 5-cm long TE left bronchus with 
the in-vivo bioreactor design was implanted to bridge 
the left lower basal segmental bronchus to the carina. 
Revascularization and reepithelialization were confirmed 
4 months postoperatively, and the patient underwent 
chemo-radiotherapy without complications related to the 
implanted TE substitute. 
Methods
The patient
A 57-year-old man who complained of coughing and 
dyspnea was referred to Shanghai Chest Hospital in January 
2015. Computed tomographic (CT) scan showed a centrally 
located mass at the left upper lobe extending to the left 
main bronchus with obstructive pneumonia. Positron 
emission tomographic (PET) indicated subcarinal lymph 
nodes metastasis. Brain magnetic resonance imaging (MRI) 
excluded brain metastasis. Bronchoscope discovered that 
the tumor had invaded the left main bronchus 2 cm distal 
to the carina and completely occluded the lumen (Figure 1). 
The biopsy confirmed squamous lung cancer, stage IIIA. 
His situation deteriorated quickly, and the patient suffered 
from left-sided entire lung atelectasis and hemoptysis. 
The oncology multidisciplinary team (MDT) decided 
that the patient was neither suitable for chemotherapy nor 
radiotherapy. MDT informed the patient that without 
any treatment his life expectancy was less than 3 months 
and surgery remained the only choice. Lung function test 
showed FEV1 1.88 64% which indicates high risk for left 
pneumonectomy. The patient refused left pneumonectomy in 
fear of poor quality of life postoperatively. On February 5th, 
2015, approved by Shanghai Chest Hospital Ethics 
Committees and with the patient’s written informed consent, 
we decided to perform salvage surgery and used the TE airway 
substitute to preserve the left lower lobe when necessary.
TE airway substitute reconstruction
We chose porcine acellularized dermis matrix (ADM) 
Figure 1 Preoperative tests. (A) Computed tomographic (CT) scan 
showed centrally located mass invading left main bronchus and 
enlarged subcarinal lymphonode; (B) bronchoscopy demonstrated 
tumor totally occluded the left main bronchus 2 cm distal from carina. 
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(Unitrump Biotech, Shanghai, China) as the biodegradable 
scaffold. A nitinol stent (MicroApproach Biotech, 
Shenzhen, China), 5 cm long and 2 cm in diameter, was 
enveloped between two layers of ADM to provide laterally 
rigid and longitudinally flexible characteristics to TE airway 
substitute. At the beginning of the operation, a 20-cm 
long, 0.5-cm wide skin strip along the chest incision 
was harvested. The skin was then cut into small pieces 
and dissociated into single cell suspension using the 
GentleMACSTM Dissociator (Miltenyi Biotec, Cologne, 
Germany). The cell suspension, mainly keratinocytes, was 
seeded onto the inner surface of the TE airway substitute 
1 hour before the implantation (Figure 2).
Operation process
Anesthesia and thoracotomy were performed as per routine. 
The left upper lobe, lower superior segment, and left 
main bronchus were resected with negative margins at 
both bronchus sections. The 5 cm long TE left bronchus 
substitute was implanted to bridge the left lower basal 
segmental bronchus to the carina. Two PORT-A-CATH 
(Smiths Medical, London, UK) catheters were inserted into 
the TE airway substitute between the two ADM layers. 
The ends of the catheters were pulled out of the thorax 
and connected to two ports embedded subcutaneously on 
the left side of chest wall (Figure 2). The two anastomoses 
were then covered with intercostal muscle flap. No air 
leakage was found during lung inflation with saline filling 
the thorax. We finally performed lymphadenectomy before 
closing the chest.
Right after the operation two infusion sets, controlled by 
two ambulatory infusion peristaltic pumps respectively (Ace 
Medical Co. Ltd., Seoul, Korea), were connected to the 
subcutaneous ports. One pump delivered Ringer’s solution 
with 100 ug/mL gentamicin continuously into the TE 
substitute while the other pump removed the waste. The 
speed of both pumps was adjusted to 10 mL/hour. 
Postoperative treatment
The patient was transferred to the ICU after the operation 
and extubated the next morning. The patient breathed 
spontaneously and X-ray showed that the left basal segment 
was well inflated. The continuous Ringer’s-gentamicin 
perfusion lasted for 1 month. On the third postoperative 
day, we harvested 20 cc blood and isolated total nucleated 
cells (TNCs) with Res-QTM 60 BMC (Cesca Therapeutics 
Inc., Rancho Cordova, CA, USA). The TNCs (0.9–1.3×108) 
were injected directly into the implanted TE substitute 
through the PORT-A-CATH system. Perfusion was paused 
for 2 hours for TNCs to adhere to the scaffold. The TNCs 
injection was performed twice a week, namely on every 
Monday and Thursday lasting for 1 month. 
Perfusate waste angiogenesis growth factor test
Perfusate wasted were collected every 4 hours and 
angiogenesis factors were measured by multiplex enzyme-
linked immunosorbent assay (ELISA) with Ciraplex™ 
technology (Aushon BioSystems, Billerica, MA, USA). 
Ciraples™ technology is antibody array based detection 
system that uses chemiluminescence to detect proteins at 
pg/mL concentrations.
The multiplex ELISAs were performed according to 
the manufacturer’s instructions. Briefly, 50 μL calibration 
standards or samples were applied to the ELISA plates, which 
were pre-washed and dried using absorbent paper. After 
a 2-hour incubation at room temperature on a horizontal 
orbital micro-plate shaker at 300 rpm and a thorough wash 
using wash buffer, 50 μL biotinylated antibody reagent was 
applied to each well of the ELISA plate and incubated for 
an additional 30 minutes using the same condition. Then, 
these plates were washed four more times using wash buffer. 
Streptavidin-HRP reagent (50 μL) was added to each 
well and incubated for 30 minutes at room temperature at 
200 rpm before processing to be imaged using the Cira CCD 
imaging system and data analyzed using the Cirasoft array 
analyst software.
Results
The patient recovered uneventfully and was transferred to 
the normal ward 1 week after the operation. He continued 
with rehabilitation and spirometry showed 10% lung 
function improvement versus the preoperative baseline. 
The patient was discharged 1 month after the surgery and 
was followed up in outpatient department.
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Figure 2 Tissue engineered (TE) airway substitute reconstruction and implantation with in-vivo bioreactor design. (A) Nitinol stent, 5 cm 
long and 2 cm in diameter; (B) porcine acellularized dermis matrix (ADM); (C) enveloped nitinol stent with two layers ADM to form TE 
airway substitute; (D) inserted two PORT-A-CATH catheters between two layers ADM of TE airway substitute; (E) skin strip harvested 
along chest incision and cut into small pieces; (F) GentleMACSTM Dissociator dissociated skin into single cell suspension; (G) seeded single 
cell suspension onto TE trachea substitute inner surface 1 hour before implantation; (H) TE airway substitute bridged left lower basal 
segmental bronchus to the carina; (I) PORT-A-CATH catheters were connected to two subcutaneously implanted ports that connected 
through needles to two ambulatory infusion peristaltic pumps respectively; (J) one pump delivered Ringer’s solution with 100 μg/mL 
gentamicin continuously into the TE substitute while the other removed the waste. Both speeds were adjusted to 10 mL/hour.
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Bronchoscopy was then checked at 2 weeks, 1 month, 2, 
3 and 4 months postoperatively. A revascularization process 
together with gradual biodegradation of the ADM scaffold 
was observed through video analysis of the TE airway 
substitute surface changing. Fully reepithelialization of 
the TE substitute was confirmed through biopsy 4 months 
postoperatively (Figure 3).
The histology result confirmed stage IIIA squamous 
lung cancer. Six months after the operation, CT showed 
mediastinal lymphonodi implicative to lung cancer relapse. 
The patient refused both endobronchial ultrasonography 
(EBUS) and mediastinoscope to confirm the diagnosis. 
We persuaded him to take two cycles of DP (docetaxol + 
cisplatin) chemotherapy and 30 Gy radiotherapy. However 
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adjuvant chemo-radiotherapy had to be stopped due to the 
patient’s severe vomiting. The patient subsequently insisted 
on taking epidermal growth factor receptor EGFR tyrosine 
kinase inhibitor, Tarcevo 150 mg q.d., although PCR test 
failed to find EGFR mutation. The patient eventually died 
of lung cancer relapse 13 months postoperatively without 
complications related to the TE substitute.
Perfusate waste angiogenesis growth factor test
Various GFs were founded in the collected perfusate waste, 
including human promote angiogenin-2 (hAng-2), human 
alkaline fibroblast growth factor (hFGF)-basic, human 
heparin combined with epidermal growth factor (hHB-
EGF), human hepatocyte growth factor (hHGF), human 
platelet-derived growth factor-BB (hPDGF-BB), human 
vascular endothelial growth factor (hVEGF), human 
placental growth factor (hPIGF). We failed to found human 
vascular endothelial growth factor C (hVEGF-C) in the 
perfusate.
Discussion
Airway reconstruction remains a challenge mainly due 
to two obstacles (13,14). First, the airway is open to the 
air full of bacteria that invade and grow in the substitute 
much faster than normal cells do. Any prosthesis with 
perfect biocompatibility will also make it susceptible to 
bacterial infection that might lead to lethal pneumonia 
and stimulate granulation tissue overgrowth obstructing 
the airway (15). Second, the trachea and bronchus are 
supplied with a network of small vessels inaccessible to 
direct revascularization through vessel anastomosis. Animal 
studies have demonstrated that even immediate autologous 
orthotropic trachea replacement longer than 2 cm is bound 
to fail, despite the fact that the fresh autograft substitute is far 
more physiological than any possible tracheal substitute (16).
The tissue engineering airway reconstruction technique 
also has to overcome these two obstacles. In our in-vivo 
bioreactor case, infection was controlled by a continuous 
Ringer’s-gentamicin perfusion inside the implanted 
TE trachea substitute. We hypothesis that it might 
maintain temporary survival of pre-seeded keratinocytes 
that might function temporary as the epithelial layer to 
prevent bacterial invasion and control granulation tissue 
regeneration. Without a suitable monitoring method, 
our results did not show direct evidence of keratinocyte 
survival and function. A successful revascularization and 
reepithelialization process without infection or granulation 
tissue overgrowth indicates the role of pre-seeded 
keratinocyte.
In-vivo bioreactor design also realized repeated cell 
seeding after TE substitute implantation. The traditional 
tissue engineering technique was composed of two absolutely 
separated stages. The first stage is in-vitro substitute 3D 
culture that is often realized in various kinds of bioreactors 
mimicking the in vivo regenerative niche (17). Ironically, 
our knowledge of tissue regeneration was too limited to 
prevent cell dedifferentiation in vitro (18). The next stage 
is regarded as the TE substitute in-vivo regeneration 
phase after implantation. During this stage, implanted TE 
substitute will go through regenerative and revascularization 
processes to become compatible to the recipient. The final 
regenerated tissue proved to be a hybrid of pre-seeded 
cells and in situ regenerative cells (19). This fact challenges 
the necessity to create a perfect TE substitute with various 
kinds of cells to maintain the 3D organization associated 
with normal organ structure. It might be more efficient and 
feasible to implant cells repeatedly together with various 
growth factors to take advantage of and even boost the 
nature regenerative capability. In our case, we use in-vivo 
bioreactor design to combine the two stages and treat 
the recipient himself as a bioreactor for his own TE left 
main bronchus reconstruction. Previous studies proved 
the effect of bone marrow stromal cells (BMSCs) in TE 
airway reconstruction, either harvested from bone marrow 
or periphery blood (20). In our study we choose periphery 
blood originated BMSC, considering that it is much more 
easier to collect repeatedly. We did not try to isolate and 
proliferate BMSCs in vitro with the concern of limited 
numbers and quickly dedifferentiation. Instead, we use 
TNCs with the view to creating synergy amongst them. 
Various angiogenesis growth factors were found in the 
perfusate waste. Since we use Ringer’s-gentamicin without 
any growth factor supplements as inlet perfusate, these 
angiogenesis growth factors should be mainly secreted 
by re-seeded cells in the ischemia niche of implanted TE 
trachea substitute. The secretion of growth factors is a 
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Figure 3 Post-operative treatment. Total nucleated cells (TNCs) (0.9–1.3×108) were harvested with Res-QTM 60 BMC and injected into 
implanted tissue engineered (TE) airway substitute for 9 times. Perfusate wastes were collected every 4 hours and various growth factors 
were demonstrated. Bronchoscopy follow-up proved a revascularization process together with gradual biodegradation of the ADM scaffold. 
Biopsy at 4-month postoperatively showed TE airway substitute reepithelialized with ciliary epithelium. Computed tomographic (CT) 
follow-up demonstrated left lung well inflation and lung function test showed FEV1 and FVC 10% improvement postoperatively. Six 
months postoperative follow-up showed mediastinal lymphadenectasis. Two cycles of DP (docetaxol + cisplatin) chemotherapy and 30 Gy 
radiotherapy were performed and had to stop due to severe vomiting. The patient insisted to take epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor although PCR test failed to find EGFR mutation. The patient died of lung cancer relapse 13 months postoperatively 
without complications related to the TE substitute.
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circumstantial evidence of re-seeded cell’s contribution to 
the regeneration of TE trachea substitute.
In lung cancer treatment, lobectomy provides lower 
postoperative morbidity, lower mortality and better survival 
results than pneumonectomy for stage AIII patients (21). The 
lobectomy patients recover quickly and are able to undergo 
adjuvant chemo-radiotherapy, which is often not tolerated 
by pneumonectomy patients. For TE airway substitute to 
be widely applied in lung cancer treatment, evidence must 
be produced that it does not undermine adjuvant chemo-
radiotherapy treatment. Our case is the first TE substitute 
implantation patient who survived chemo-radiotherapy. This 
fact indicates a complete left main bronchus regeneration 
perfectly integrated to normal airway tissue.
Conclusions
Our work proves the possibility of in-vivo bioreactor 
design to be used in airway reconstruction. It modified the 
traditional TE technique by integrating the in-vitro and 
in-vivo stages and treating the recipient as a bioreactor 
of his own TE airway regeneration. To the best of our 
knowledge, this is the first report of a TE airway patient 
tolerating chemo-radiotherapy.
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